Altering Gut Microbiome May Improve ICI Outcomes in RCC
John SchieszerJun 5, 2018Making some changes to the gut microbiome may improve outcomes with immune checkpoint inhibitors in renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Hot Chemo Fails in Rare Cancer
(MedPage Today) -- HIPEC and surgery equals surgery alone in peritoneal carcinomatosis (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 4, 2018 Category: Gastroenterology Source Type: news

ASCO: Sunitinib Alone Noninferior in Metastatic Renal Cell Cancer
MONDAY, June 4, 2018 -- For patients with metastatic renal cell carcinoma classified as having intermediate or poor prognostic risk, sunitinib alone is noninferior to nephrectomy and sunitinib, according to a study published online June 3 in the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2018 Category: Pharmaceuticals Source Type: news

No OS Benefit From HIPEC in Colorectal Cancer
Bryant FurlowJun 4, 2018Overall, patients with mCRC and isolated peritoneal carcinomatosis did not benefit when hyperthermic intraperitoneal chemotherapy was added to surgery. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Combines Blueprint Medicines' Lead Clinical Programs with CStone Pharmaceutical's Regional Expertise Expands BLU-554 Development Program in Hepatocellular Carcinoma with Plans to Bring Ongoing Monotherapy Trial to China and Initiate Proof-of-Concept Com... Biopharmaceuticals, Oncology, Licensing Blueprint Medicines, CStone Pharmaceuticals, Avapritinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 4, 2018 Category: Pharmaceuticals Source Type: news

In Advanced Kidney Cancer, Surgery No Longer Standard of Care In Advanced Kidney Cancer, Surgery No Longer Standard of Care
The management of patients with metastatic renal cell carcinoma has changed with the advent of targeted therapy. Now a major clinical trial indicates that those drugs alone are sufficient for many of these patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

In Advanced Kidney Cancer, Surgery No Longer Sole Standard of Care In Advanced Kidney Cancer, Surgery No Longer Sole Standard of Care
The management of patients with metastatic renal cell carcinoma has changed with the advent of targeted therapy. Now a major clinical trial indicates that those drugs alone are sufficient for many of these patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Many With Metastatic Kidney Cancer Can Forego Surgery
Bryant FurlowJun 3, 2018For many patients diagnosed with metastatic renal cell carcinoma, sunitinib alone is not inferior to surgery followed by sunitinib. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Nektar Pharmaceuticals and Bristol-Myers Squibb said results for their experimental cancer drug, NKTR-214, pushing forward into late-stage trials testing the medicine against melanoma, renal cell carcinoma, and urothelial cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 2, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:NKTR NYSE:BMY Source Type: news

Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
SINGAPORE, May 28, 2018 -- (Healthcare Sales & Marketing Network) -- Lion TCR Pte Ltd, a clinical stage biotech pioneering T cell therapy against viral- related cancer, announced today they have raised US$ 20 million in its Series A financing round. The m... Biopharmaceuticals, Oncology, Venture Capital Lion TCR, LioCyx, T-cell, Hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 28, 2018 Category: Pharmaceuticals Source Type: news

Karl Storz Focuses on Bladder Cancer Detection With New Device
Karl Storz is focusing on bladder cancer detection with its latest product. The El Segunda, CA-based company said it is launching the PDD Blue Light Flexible Video Cytoscopy System. The product launch follows the approval of a supplemental new drug application and a premarket approval supplement from FDA extending the indication for Blue Light Cystoscopy with Cysview (BLCC) to include use of the new Karl Storz PDD Blue Light Flexible Video Cystoscope. Also included in the approval is an expanded indication for the repetitive use of Cysview within the same patient and for the identification of Carcinoma in Situ (CIS); one o...
Source: MDDI - May 18, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Real-World Evidence from McKesson Supports First-Ever FDA Approval for Metastatic Merkel Cell Carcinoma Drug
The Woodlands, Texas (May 16, 2018) — A powerful, real-world evidence study designed by McKesson Specialty Health for its biopharma partner played a key role in the Food and Drug Administration’s (FDA) approval for first-line indication for a rare disease. Recently “Merkel Cell Carcinoma Observation... (Source: McKesson News)
Source: McKesson News - May 16, 2018 Category: Information Technology Source Type: news

Spontaneous Regression of a Squamous Cell Lung Cancer Spontaneous Regression of a Squamous Cell Lung Cancer
What might be the mechanism behind the spontaneous regression of this patient's stage I squamous cell lung carcinoma?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Should You Stop Wearing Sunscreen To Get More Vitamin D? Here ’s What a Doctor Says
Last year, a study published in The Journal of the American Osteopathic Association made headlines when it asserted that sunscreen use is partially to blame for widespread vitamin D deficiency worldwide. The research raised questions, given that consistently wearing sunscreen is one of the most common pieces of advice from physicians. Should the risk of vitamin D deficiency — which can lead to brittle bones and has been associated with insulin resistance, high blood pressure and decreased immune function, among other issues — overshadow years of that advice? Not according to Dr. Victoria Werth, a professor of d...
Source: TIME: Health - May 14, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime onetime public health Source Type: news

CRC Polyps May Allow for Immune Checkpoint Inhibitors in Premalignant Lesions
Colorectal carcinomas in LS patients appear in background of mismatch repair (MMR) deficiency, show a unique immune profile, and response to immunotherapy. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer Gastrointestinal Cancer News Source Type: news

Depleted metabolic enzymes promote tumor growth in kidney cancer
(University of Pennsylvania School of Medicine) By integrating data on the function of essential metabolic enzymes with genetic, protein, and metabolic abnormalities associated with " clear cell " renal cell carcinoma (ccRCC), researchers have determined that enzymes important in multiple pathways are universally depleted in ccRCC tumors. Kidney cancer, one of the ten most prevalent malignancies in the world, has increased in incidence over the last decade, likely due to rising obesity rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 10, 2018 Category: Cancer & Oncology Source Type: news

Patient and Tumor Features Predicted RCC Outcomes Post Nephrectomy
Routinely available patient and tumor features accurately predicted the risk progression and death from RCC post nephrectomy, a Mayo Clinic team found. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Type 2 Diabetes Ups Risk of Renal Cancer in Women, but Not Men
TUESDAY, May 8, 2018 -- Type 2 diabetes is independently associated with a greater risk of renal cell carcinoma (RCC) in women, but not in men, according to a study published online April 20 in Diabetes Care. Rebecca E. Graff, Sc.D., from Harvard... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 8, 2018 Category: Pharmaceuticals Source Type: news

New biomarker identified for early diagnosis of lung cancer
(Elsevier) In a novel study in The American Journal of Pathology investigators found that CKAP4 levels were significantly higher in patients with lung cancer than in healthy individuals. They further determined that CKAP4 levels are already elevated in the blood of patients with stage I disease, making it a potential noninvasive diagnostic marker that could change current practices in the diagnosis and treatment of some types of lung cancer, including non-small-cell lung cancer and squamous cell carcinoma, and improve patient outcomes. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 8, 2018 Category: Biology Source Type: news

NSAID Use Associated With Shorter PFS, OS in Metastatic RCC
A pooled retrospective analysis of nearly 5,000 mRCC patients in phase II and III trials showed PFS among NSAIDs users was half that of NSAIDs nonusers. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: News Renal Cell Carcinoma Source Type: news

New CABOSUN Data Show Better PFS With Cabozantinib in mRCC
The significantly better PFS compared with sunitinib supports cabozantinib as initial therapy for patients with advanced RCC of intermediate or poor risk. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Renal Cell Carcinoma Source Type: news

When TKI Sunitinib Can Be Discontinued in Metastatic RCC When TKI Sunitinib Can Be Discontinued in Metastatic RCC
Can sunitinib be discontinued in patients with stable metastatic renal cell carcinoma without negatively impacting outcomes?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Use of ibuprofen and similar NSAIDs may shorten life of patients
(IOS Press) Ibuprofen, aspirin, and other non-steroidal anti-inflammatory medications are among the most commonly utilized medications in the United States. Primarily for treating pain, inflammation, and preventing cardiovascular disease, NSAIDs' promising anti-cancer properties have been highlighted by a growing body of data in recent years. However, a new study in the journal Kidney Cancer indicated that non-aspirin NSAID use was associated with shorter overall survival in patients with metastatic renal cell carcinoma (mRCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2018 Category: International Medicine & Public Health Source Type: news

FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
TARRYTOWN, N.Y. and PARIS, April 30, 2018 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologic... Biopharmaceuticals, Oncology, FDA Regeneron Pharmaceuticals, Sanofi, cemiplimab, squamous cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2018 Category: Pharmaceuticals Source Type: news

International team discovers a new anti-cancer protein and it could help doctors treat liver cancer better
(Natural News) Liver cancer is on the rise, with the number of cases tripling in the U.S. since the 1980s. Around 31,000 Americans develop the disease in every year, and 24,000 people die from it. Unfortunately, patients with hepatocellular carcinoma generally have a poor overall prognosis because it’s typically diagnosed in the later stages when... (Source: NaturalNews.com)
Source: NaturalNews.com - April 30, 2018 Category: Consumer Health News Source Type: news

FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
PARIS and TARRYTOWN, N.Y., April 30, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 30, 2018 Category: Drugs & Pharmacology Source Type: news

What Causes Flushing?
Discussion Flushing is usually thought of as a benign condition such as blushing, but can be quite irritating if it is frequent or persistent (i.e. menopausal hot flashes) or even pathologic (i.e. malignancy). “Flushing is a subjective and sensation of warmth that is accompanied by reddening of the skin anywhere on the body but favors the face, neck, and upper torso…. Flushing can be broadly divided into episodic or persistent. Episodic flashing is mediated by the release of endogenous vasoactive mediators or medications, while persistent flushing result in a fixed facial erythema with telangiectasias and cyan...
Source: PediatricEducation.org - April 30, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Preferred First-line Treatment for Metastatic Kidney Cancer Preferred First-line Treatment for Metastatic Kidney Cancer
Indirect comparisons suggest that of available agents, cabozantinib or nivolumab plus ipilimumab may be the most effective first-line treatment for metastatic renal-cell carcinoma.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Proactive Swallowing Rehab Program Helpful in Phalangeal CA
THURSDAY, April 26, 2018 -- A proactive speech and language pathology (SLP) program is beneficial for patients with head and neck squamous cell carcinoma (HNSCC), according to a study published online April 19 in JAMA Otolaryngology-Head& Neck... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 26, 2018 Category: Pharmaceuticals Source Type: news

A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment
The limited ability of cytotoxic T cells to infiltrate solid tumors hampers immune surveillance and the efficacy of immunotherapies in cancer. Adenosine accumulates in solid tumors and inhibits tumor-specific T cells. Adenosine inhibits T cell motility through the A2A receptor (A2AR) and suppression of KCa3.1 channels. We conducted three-dimensional chemotaxis experiments to elucidate the effect of adenosine on the migration of peripheral blood CD8+ T cells from head and neck squamous cell carcinoma (HNSCC) patients. The chemotaxis of HNSCC CD8+ T cells was reduced in the presence of adenosine, and the effect was greater o...
Source: Signal Transduction Knowledge Environment - April 24, 2018 Category: Science Authors: Chimote, A. A., Balajthy, A., Arnold, M. J., Newton, H. S., Hajdu, P., Qualtieri, J., Wise-Draper, T., Conforti, L. Tags: STKE Research Articles Source Type: news

NCCN: Screen for Liver Cancer in Patients at Risk NCCN: Screen for Liver Cancer in Patients at Risk
Hepatocellular carcinoma is a'bad actor'with a growing death toll in the United States and Europe; when possible, patients with risk factors should be screened.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

DAA Treatment for Patients With Hepatocellular Carcinoma DAA Treatment for Patients With Hepatocellular Carcinoma
What factors need to be considered when using DAAs for HCV in patients with HCC? Review recent findings surrounding indications, efficacy and outcomes associated with DAA treatment in these patients.Current Opinion in Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 23, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Vitamin A derivative selectively kills liver cancer stem cells
(RIKEN) Acyclic retinoid, an artificial compound derived from vitamin A, has been found to prevent the recurrence of hepatocellular carcinoma (HCC), the most common form of liver cancer. Now, in research published in Proceedings of the National Academy of Sciences, scientists have discovered that the compound targets one class of cancer stem cells, preventing them from giving rise to new tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2018 Category: Cancer & Oncology Source Type: news

Nivolumab/Ipilimumab Combo Approved for Advanced RCC
In a pivotal trial, combination of nivolumab and ipilimumab yielded improvement in OS and ORR of poor-risk RCC patients. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2018 Category: Cancer & Oncology Authors: Dylan Fisher Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Most Smokers With Head and Neck Cancer Have Tried to Quit
THURSDAY, April 19, 2018 -- Most active smokers with head and neck squamous cell carcinoma (HNSCC) have made one or more quit attempts, according to a study published online April 12 in JAMA Otolaryngology-Head& Neck Surgery. Samir S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2018 Category: Pharmaceuticals Source Type: news

Sensus Healthcare inks multiple distro deals, launches global expansion project
Superficial radiation therapy device developer Sensus Healthcare (NSDQ:SRTSU) today released plans for a global expansion, including new distribution agreements in China, Germany, Mexico, Cuba and Costa Rica. Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids. The Boca Raton, Fla.-based company refers to the technology as superficial radiation therapy, and claims that the tech has been sued to “effectively and safely treat oncological and non-oncological skin conditions.” “Following our new partnersh...
Source: Mass Device - April 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Distribution Oncology Sensus Healthcare LLC Source Type: news

Immunotherapy Prolongs Hepatocellular Carcinoma Survival Immunotherapy Prolongs Hepatocellular Carcinoma Survival
The benefits of immunotherapy with cytokine-induced killer cells continue to be seen in a follow-up extension study of patients with hepatocellular carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

New Drug Combo Ups Survival in HER2/neu Uterine Serous Cancer
WEDNESDAY, April 18, 2018 -- For patients with human epidermal growth factor receptor 2 (HER2)/neu-positive uterine serous carcinoma, adding intravenous trastuzumab to treatment with carboplatin-paclitaxel is associated with increased... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2018 Category: Pharmaceuticals Source Type: news

FDA approves combination for advanced renal cell carcinoma
The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label trial. Patients with previously untreated advanced RCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses followed by nivolumab monotherapy (3 mg/kg) every 2 weeks, or sunitinib 50 mg daily for 4 weeks followed by 2 weeks off every cycle.04/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 17, 2018 Category: Urology & Nephrology Source Type: news

Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
Antibiotics administered within 30 days of starting immunotherapy reduced both PFS and OS for patients with advanced RCC and NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - April 16, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

FDA Approves IO Combo for Advanced Renal Cell Cancer FDA Approves IO Combo for Advanced Renal Cell Cancer
The approval of the nivolumab and ipilimumab combination provides a new first-line treatment option for a segment of patients with advanced renal cell carcinoma.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) April 16, 2018 --Bristol-Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 16, 2018 Category: Drugs & Pharmacology Source Type: news

Trastuzumab Effective in Uterine Serous Carcinoma (CME/CE)
(MedPage Today) -- In patients overexpressing HER2, a 5-month boost in PFS when added to carboplatin-paclitaxel (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 14, 2018 Category: Hematology Source Type: news

Inhibiting metabolism found to be effective in treating aggressive form of lung cancer
FINDINGSResearchers from UCLA and Long Beach Memorial Medical Center have found that two targeted therapies could be more effective if used in combination to treat squamous cell carcinomas of the lung. The two drugs, MLN128 and CB-839, individually target the metabolism of key nutrients glucose and glutamine, respectively, prohibiting the cancer from switching metabolic gears between glucose (a simple sugar) and glutamine (an amino acid) to tap vital sources of energy. This switch enables the cancer cells to adapt their metabolism and evade treatments.BACKGROUNDNon-small cell lung cancer makes up about 85 percent of all lu...
Source: UCLA Newsroom: Health Sciences - April 13, 2018 Category: Universities & Medical Training Source Type: news

US study reports dramatic reduction in likelihood of liver transplantation in patients with hepatoce
(European Association for the Study of the Liver) ILC 2018: Although hepatocellular carcinoma is now the leading indication for liver transplantation in the USA, the probability of patients receiving a transplant has declined significantly in recent years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2018 Category: International Medicine & Public Health Source Type: news

Selective internal radiation therapy (SIRT) fails to extend survival in the SORAMIC study palliative cohort
(European Association for the Study of the Liver) ILC 2018: The addition of SIRT to sorafenib in patients with advanced hepatocellular carcinoma was associated with no overall survival benefits compared with sorafenib alone, but may offer benefits in some subgroups of patients (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 13, 2018 Category: Cancer & Oncology Source Type: news

Inhibiting metabolism found to be effective in treating aggressive form of lung cancer
(University of California - Los Angeles Health Sciences) Researchers from UCLA and Long Beach Memorial Medical Center have found that two targeted therapies could be more effective if used in combination to treat squamous cell carcinomas of the lung (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2018 Category: Cancer & Oncology Source Type: news

Screening for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis achieving sustained virological response is likely to be cost effective
(European Association for the Study of the Liver) A Canadian study suggests that biannual or annual ultrasound screening for HCC is likely to be cost effective after a sustained virological response in those with hepatitis C-related cirrhosis, but not in those with advanced fibrosis without cirrhosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2018 Category: Cancer & Oncology Source Type: news

Sensitive new assay detects hepatitis B infection in single liver cells and serum
(Elsevier) Chronic hepatitis B virus (HBV) can progress to cirrhosis and hepatocellular carcinoma (HCC). A study published in The Journal of Molecular Diagnostics describes a new HBV assay that offers advantages over currently used methods because it has the capability to detect closed circular DNA (cccDNA) in serum, single cells, and preserved tissue samples. This assay can be used to diagnose HCC at an earlier stage to manage treatment more effectively. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 12, 2018 Category: International Medicine & Public Health Source Type: news

Drop in Thyroidectomy Rates for Thyroid Carcinoma Drop in Thyroidectomy Rates for Thyroid Carcinoma
The rates of upfront total thyroidectomy and completion thyroidectomy for well-differentiated thyroid carcinoma (WDTC) have decreased since implementation of the updated 2015 American Thyroid Association guidelines.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 10, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news